ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (AMEX:RNN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, announced today that it has been added to the broad-market Russell 3000® Index as part of Russell Investments’ recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred on June 27, 2008.
